QRxPharma Makes Pain Connection By Teaching Old Drugs New Tricks
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Sydney-headquartered QRxPharma formed a development deal with China Aoxing Pharmaceutical for QRxPharma's lead candidate MoxDuo IV, an intravenous formulation of morphine and oxycodone for treating moderate to severe pain